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Abstract
Objective: Pentraxins like C-reactive protein are key components of the innate immune system. Recently, pentraxin-3 (PTX3)
has been proposed to be a specific marker of vascular inflammation, yet its association with atherosclerosis is still unclear.
Methods and Results: PTX3 serum levels were measured in three independent studies of 132 young men (ARMY Study),
205 young women (ARFY Study) and 562 individuals 55 to 94 years old (Bruneck Study). In contrast to C-reactive protein,
PTX3 showed little relationships with classic vascular risk factors and pro-inflammatory conditions. In the population
based Bruneck Study, PTX3 level was independently associated with prevalent cardiovascular diseases (multivariable odds
ratio [95%CI] 3.09 [1.65–5.79]; P,0.001). Moreover, PTX3 level correlated with the severity of carotid and femoral
atherosclerosis and was highest in individuals with multiple vascular territories affected. In contrast, there was no
association with elevated intima-media thickness, a precursor lesion of atherosclerosis, in any of the three populations
investigated.
Conclusions: Level of PTX3 is independently associated with atherosclerosis and manifest cardiovascular disease but not
early vessel pathology. Unlike C-reactive protein, PTX3 is not a component of the classic acute phase response (systemic
inflammation) but appears to be more specific for vascular inflammation.
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Introduction
It is well documented, that immunological and inflammatory
processes play a fundamental role in atherogenesis.[1–3] Pentrax-
ins are key components of the humoral arm of the innate immune
system.[4] The best known member of this protein family is C-
reactive protein (CRP), a short pentraxin. Recently a long
pentraxin – pentraxin-3 (PTX3) – has moved into the focus of
research. It is expressed in monocytes, macrophages, endothelical
cells, dentritic cells, fibroblasts and epithelial cells [4] – all of which
are present in the vascular wall and increased in atherosclerotic
plaques – and therefore a potential specific marker of inflamma-
tion and atherosclerotic changes of the vascular wall.[5–7] High
PTX3 levels have been associated with unstable angina [8],
adverse outcome after myocardial infarction [9] and heart failure
[10]. In a subsample of the Cardiovascular Health Study, baseline
PTX3 was associated with cardiovascular and all cause mortality,
yet not with incident angina or myocardial infarction [11]. In
contrast to CRP, which has a recent evolutionary history, PTX3 is
structurally highly conserved from mice to men.[4] It shows little
correlations with standard vascular risk factors [11], is not
produced in the liver but locally in atherosclerotic lesions
themselves [12] and was reported to accumulate during athero-
sclerosis progression in a murine model [13] - making PTX3 a
promising and more specific marker for vascular inflammation.
The current study is the first to explore the association of PTX3
level with in vivo measurements of atherosclerosis in three
independent population studies.
Methods
Ethics Statement
All participants gave a written informed consent, and each study
was approved by the corresponding ethics committees (Innsbruck,
Austria for the ARMY and ARFY studies and Bolzano, Italy for
the Bruneck study).
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Study Design
The Bruneck study is a prospective population-based survey of
the epidemiology and pathogenesis of atherosclerosis. At the 1990
baseline evaluation, the study population was recruited as a sex-
and age-stratified random sample of all inhabitants of Bruneck
(Bolzano Province, Italy) 40–79 years old (125 women and 125
men in the fifth to eighth decades each; n= 1000). A total of
93.6% participated, with the original data assessment completed
for 919 subjects. The present investigation focused on the 2005 re-
evaluation and involved 562 study participants aged 55–94 years
(all Caucasians). Based on the questionnaires and logistics of the
Bruneck Study two cross-sectional studies of young men and
women were designed:
The Atherosclerosis Risk Factors in Male Youngsters (ARMY)
Study is a cross-sectional evaluation of young men performed in
2001. In Austria, every male citizen undergoes a thorough physical
examination by experienced medical personnel to assess physical
fitness for recruitment into the Austrian army in the year he turns
18 - except for those suffering from chronic diseases (e.g. diabetes)
or permanent disabilities (,1.5%). In 132 of the initially
participating 141 individuals sufficient amounts of serums samples
were available (stored at 280uC) for measurement of PTX3.
The Atherosclerosis Risk Factor in Female Youngsters (ARFY)
Study is a cross-sectional ultrasound-based evaluation of risk
factors for early vessel pathology in young women. Between
April and June 2005, all female students of the Educational
Centre West for Allied Health Professions (Innsbruck, Austria),
18 to 22 years old, were invited to participate. A total of 211
women, all upcoming healthcare professionals (nurses, medical
technicians, physiotherapists, occupational therapists, logope-
dics, and dieticians) accepted the invitation. All participants were
white and none had a history of cardiovascular disease. Data
assessment was complete in 205 women, who formed the current
study population. The three studies were similar in design,
logistics and methodology. Details have been published be-
fore.[14–17]
Clinical history and examination
The participants of the three studies underwent a thorough
clinical examination and completed the same standardized
questionnaires on current and past exposure to vascular risk
factors. Waist was measured at the narrowest point between the
costal margin and the iliac crest (on the naked abdomen). Body
mass index (BMI) was calculated as body weight divided by the
square of the height (in meters). The average number of cigarettes
smoked per day was noted for each smoker and ex-smoker.
Subjects were categorized as ‘‘smokers’’ if they reported regular
consumption of .1 cigarette per week and lifetime consumption
exceeded 40 cigarettes. Cigarette pack-years were calculated by
multiplying the years of smoking by the packs smoked per day.
Subjects were instructed to indicate their customary alcohol
consumption during a typical day (in the case of regular alcohol
consumption) or week (all alcoholic beverages consumed on
weekdays and the weekend). Average alcohol intake was expressed
as grams of ethanol per day and calculated from responses
concerning the various types and amounts of alcoholic beverages
consumed. Office blood pressure readings were taken after at least
10 minutes of rest and calculated as a mean of three independent
readings. Hypertension was defined as blood pressure $140/
90 mmHg or use of antihypertensive drugs. Social status was
deduced from occupation of the household member with the
highest income.[15] The sport index was calculated according to
the Baecke formula.[18] Diabetes mellitus was diagnosed if the
subject was being treated with insulin or oral hypoglycemic drugs,
if the subject’s fasting plasma level of glucose exceeded 140 mg/
dL, and/or if the 2-hour value after oral glucose loading exceeded
200 mg/dL. Chronic infections and conditions known to be
associated with recurrent episodes of infectious exacerbations were
diagnosed after a detailed interview of the participant and a review
of medical records.[15]
The same detailed procedure lead to the diagnosis of a history of
cardiovascular diseases (composite of stroke, TIA, myocardial
infarction, peripheral artery disease, definite angina and previous
Figure 1. Distribution of PTX3 levels in the Bruneck (black), ARMY (blue) and ARFY (pink) study.
doi:10.1371/journal.pone.0031474.g001
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revascularization procedures). Myocardial infarction was deemed
confirmed when World Health Organization criteria for definite
disease status were met. Ischemic stroke and transient ischemic
attacks were classified according to the criteria of the National
Survey of Stroke. The diagnosis of symptomatic peripheral artery
disease and angina pectoris required a positive response to the Rose
questionnaire with the vascular nature of complaints confirmed by
standard diagnostic procedures (ankle-brachial pressure index or
angiography and exercise electrocardiogram or coronary angiog-
raphy). Revascularization procedures (angioplasty and surgery)
were carefully recorded. Ascertainment of events or procedures did
not rely on hospital discharge codes or the patient’s self-report but
on a careful review of medical records provided by the general
practitioners, death certificates, and Bruneck Hospital files, and the
extensive clinical and laboratory examinations performed as part of
the study protocols. Major advantages of the Bruneck Study are that
virtually all subjects living in the Bruneck area were referred to the
local hospital and that the network existing between the local
hospital and the general practitioners allowed retrieval of practically
all medical information on persons living in the area.
Laboratory Methods
Blood samples were taken from the antecubital vein after
subjects had fasted and abstained from smoking for .12 hours.
CRP (hsCRP) was measured by immunonephelometry (Dade,
Behring, Marburg, Germany) with a intra- and interassay
coefficient of variation of 3.7%. Other standard lab parameters
were measured by routine methods applied in the central lab
Table 1. Population characteristics according to PTX3 tertile groups in the Bruneck Study.
Tertile of PTX3 serum level [ng/mL]a P value
Low Medium High PTX3b
PTX3 (ng/mL)
mean6SD 1.3260.30 2.1160.20 3.4361.87
Range 0.48–1.75 1.76–2.46 2.47–26.52
Demographic variables
Age – years 67.1668.7 68.6269.747 71.9269.76 0.054
Men – n (%) 83 (44.4) 94(50) 82(43.9) 0.607
Lifestyle factors
Waist circumference – cm 91.92611.22 92.36611.76 89.78613.20 0.041
Body mass index – kg/m2 26.4063.84 26.2064.00 25.3164.50 0.016
Physical activity – score 2.4660.72 2.4360.75 2.2960.63 0.042
Alcohol consumption – g/day 14.98620.64 20.65628.20 18.55626.11 0.154
Smoking – pack-years 10.88615.46 11.76615.95 14.31618.98 0.180
Vascular risk factors
Diabetes mellitus – n (%) 14(7.5) 18(9.6) 26 (13.9) 0.100
Hypertension – n (%) 115 (61.5) 132 (70.2) 135 (72.2) 0.248
Fasting glucose – mg/dl 101.20617.36 102.52618.30 105.12629.58 0.036
HbA1c – % 5.6760.54 5.7560.72 5.8260.81 0.423
HDL-Cholesterol – mg/dL 63.63613.24 64.17614.82 64.34613.86 0.436
LDL- Cholesterol – mg/dL 138.33632.10 137.11634.61 131.83636.27 0.942
Triglycericdes d – mg/dL 119(94–165) 113(90–152) 114(91–155) 0.114
Lipoprotein(a) d – mg/dL 0.14(0.05–0.33) 0.15(0.05–0.47) 0.15(0.59–0.45) 0.512
Urinary ACR d – mg/g 6.2(3.6–14.5) 5.9(3.73–10.93) 8.9(4.6–23.1) 0.002
Fibrinogen d – mg/dL 286(254–318) 290(258–319) 301(271–352) 0.018
Inflammatory Parameters
Chronic infection – n(%) 39 (20.9) 44 (23.4) 64 (34.2) 0.207
hsCRP– mg/dL 0.17(0.11–0.39) 0.18(0.10–0.39) 0.23(0.12–0.67) 0.004
Neutrophil count –/L 3277(2582–3930) 3386(2681–4436) 3752(3070–4787) ,0.001
MMP-9 – ng/mL 50.1(27.4–83.9) 66.3(33.1–92.0) 92.4(50.5–92.4) ,0.001
G-CSF – pg/mL 8.77(3.53–15.54) 9.57(5.23–15.53) 9.67(4.86–21.10) 0.402
SDF-1 – pg/mL 2486(2261–2823) 2501(2226–2806) 2620(2313–2974) 0.270
VEGF – pg/mL 61.4(24.1–140.6) 73.9(18.6–139.8) 91.9(46.2–169.8) 0.302
aValues presented are means6SD, medians (IQR) or numbers (%).
bP values are for trend and derived from age- and sex-adjusted linear or logistic regression analysis of each variable on loge-transformed PTX3 level. When correcting for
multiple testing, a P value,0.002 (in bold) indicates statistical significance (Bonferroni adjustment).
Urinary ACR – Urinary albumin-to-creatinine ratio; hsCRP – high-sensitivity C-reactive Protein; MMP-9 – matrix metalloproteinase-9; G-CSF – granulocyte colony
stimulating factor; SDF-1 – stromal cell-derived factor-1; VEGF – vascular endothelial growth factor.
doi:10.1371/journal.pone.0031474.t001
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facilities of Innsbruck University Clinics or Bruneck Hospital and
have been described previously.[15–17]
PTX3 was measured by an in-house assay based on the murine
monoclonal antibody MNB4 as capturing, and a rabbit antiserum
(pAb) raised against human PTX3, affinity purified and biotiny-
lated, as detection antibody. Streptavidin-horse radish peroxidase
was used and absorbance at 450 mm (Abs450) was measured with an
automatic ELISA reader. No cross reaction of MNB4 and pAb with
human CRP and serum amyloid P component protein has been
observed. For each biological sample, 2 dilutions in duplicate wells
were evaluated and mean PTX3 content was calculated converting
Abs450 values to protein concentration by means of a standard curve
with recombinant purified human PTX3 (range from 75 pg/ml to
2.4 ng/ml). Detection limit of our assay is 100 pg/ml and the inter-
assay variability ranges from 8 to 10%.[9]
Plasma G-CSF, SDF1-a, VEGF and MMP-9 levels were
determined using commercially available kits (Quantikine, R&D
Systems, UK) with the following intra/interassay coefficients of
variation: G-CSF 3.6–6.2%/6.3–8.2%, SDF1-a 3.4–3.9%/8.2–
13.4%, VEGF 4.5–6.7%/6.2–8.8% and MMP-9 1.9–2.9%/6.9–
7.9%. All ELISA tests were carried out at room temperature on
freshly thawed plasma samples. The concentration of all cytokines
was determined by comparison with a standard curve, following
manufacturer’s instruction.
Measurement of atherosclerosis
All participants underwent high-resolution B-mode ultraso-
nography with a 10 MHz imaging probe (ATL8 in the Bruneck
and HDI3000 in the ARMY Study, both ATL Ultrasound,
Bothell, Washington and General Electric Logic 7 in the ARFY
Study, Milwaukee, Wisconsin). The scanning protocol involved
the common carotid artery (CCA), the carotid bulb and internal
carotid artery (ICA) at both sides. In addition femoral arteries
were visualized in the Bruneck and the ARMY Study. All scans
were using the same protocol with different scanning angles
(anterior and posterolateral) employed to identify the greatest
wall and plaque thickness and all measurements were performed
by one and the same experienced sonographer (J.W.). The
intima-media thickness (IMT) was assessed at the far wall as the
distance between the interface of the lumen and intima, and the
interface between the media and adventitia (Bruneck Study:
intra-observer coefficient of variation, 7.9 percent (n = 100)). The
maximal IMT was recorded and averaged for the left and right
sides of the CCA (30 mm proximal to the carotid bulb), the
carotid bulb, the ICA and the femoral artery (40 mm proximal
to 10 mm distal of the bifurcation into the superficial and deep
branches). As no normal values exist for young individuals ‘‘high
IMT’’ in the ARFY and ARMY studies was assumed when the
IMT value exceeded the 90th percentile of IMT distribution in
one or more of the segments explored. In the Bruneck Study,
atherosclerotic lesions were defined by 2 ultrasound criteria: [1]
wall surface (protrusion into the lumen) and [2] wall texture
(echogenicity). The maximum axial diameter of plaques was
assessed in the following vessel segments on the near and far wall
of either side: proximal CCA (15 to 30 mm proximal to the
carotid bulb), distal CCA (,15 proximal to the carotid bulb),
proximal ICA (carotid bulb and initial 10 mm of the ICA), distal
ICA (.10 mm above the flow divider), femoral artery (40 mm
proximal to 10 mm distal of the bifurcation into the superficial
and deep branches). The Atherosclerosis Score (AS) was
calculated by addition of all plaque diameters of the carotid
arteries (16 sites, intra-observer coefficient of variation, 13.5
percent (n = 100)) and the femoral arteries (2 sites). Ultrasound
methodology has been extensively described previous-
ly.[14,16,17]
Table 2. Population characteristics according to CRP tertile groups in the Bruneck Study.
Tertile of CRP serum level [mg/L]a P value
Low Medium High hsCRPb
CRP (mg/L)
Mean6SD 0.8860.34 2.0960.45 9.2461.07
Range 0.02–1.4 1.5–3.2 3.3–75.40
Demographic variables
Age – years 67.869.3 68.969.5 71.069.8 ,0.001
Men – n (%) 95 (48.2) 78 (45.1) 85 (44.7) 0.568
Lifestyle factors
Waist circumference – cm 88.1611.6 90.7611.8 95.3611.8 ,0.001
Body mass index – kg/m2 24.963.8 25.963.7 27.264.5 ,0.001
Physical activity – score 2.4660.72 2.4360.68 2.2760.70 0.036
Alcohol consumption – g/day 19.7627.8 16.9623.9 17.5623.7 0.365
Smoking – pack-years 11.2614.6 9.9614.9 15.4620.1 0.001
Vascular risk factors
Diabetes mellitus – n (%) 15 (7.6) 15 (8.6) 28 (14.7) 0.016
Hypertension – n (%) 115 (58.4) 118 (67.4) 149 (78.4) ,0.001
Fasting glucose – mg/dl 101.5624.7 101.5616.5 105.8624.5 0.071
HbA1c – % 5.6660.63 5.7360.54 5.8660.88 0.016
HDL-Cholesterol – mg/dL 66.9614.2 63.9613.5 61.2613.6 ,0.001
LDL- Cholesterol – mg/dL 136.1633.8 135.86632.33 135.87637.04 0.937
doi:10.1371/journal.pone.0031474.t002
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Statistical Analysis
For statistical analysis the SPSS software package (version 18.0)
was used. Continuous variables were presented as means or
medians [inter-quartile range] and dichotomous variables as
numbers (percentages). Participants were divided into three
approximately equally sized groups according to tertiles of PTX3
(or hsCRP). Comparison of variable levels across these groups was
performed using linear regression and logistic regression analysis of
the variable of interest on age, sex and loge-transformed PTX3 or
hsCRP level (P value for trend). Base models were adjusted for age
and sex, multivariable models by age, sex, diabetes, hypertension,
HDL and LDL cholesterol, smoking, BMI and waist circumference.
To estimate the discriminative value of prediction models, i.e. the
ability to correctly classify subjects into one of two categories, we
calculated the C statistic, which is analogous to the area under the
receiver-operating-characteristic curve (ROC) (larger values indi-
cate better discrimination). Comparison of ROCs based on models
including and not including PTX3 or hsCRP was performed
according to the method of DeLong.[19] To assess model
calibration or how closely the predicted probabilities reflect actual
risk, we computed the Hosmer-Lemeshow calibration statistics
comparing observed and predicted risk in decile categories of
predicted risk (higher P values indicate better calibration). Not
normally distributed variables were log-transformed (PTX3 and
hsCPR). P-values#0.05 were considered significant. When appro-
priate, Bonferroni adjustment of P values was applied.
Results
Median (IQR) PTX3 levels amounted 2.13 ng/mL (1.55–
2.73) in the Bruneck (n = 562), 1.62 ng/mL (1.01–2.18) in the
ARMY (n = 132) and 1.37 ng/mL (0.94–2.13) in the ARFY
Study (n = 207). Distributions of PTX3 levels are depicted in
Figure 1. In the Bruneck study representing a middle-aged and
elderly male and female population, no differences in age and
sex were observed across PTX3 tertile groups (Table 1). After
adjustment for multiple testing, significant age- and sex-adjusted
associations were found for neutrophil count and matrix-
metalloproteinase 9 (MMP-9) level however not for chronic
infection and pro-inflammatory vascular risk conditions (Table 1).
The same analysis revealed numerous associations for hsCRP
(Table 2).
Next, we analyzed for a potential association between IMT - a
measure of early vessel pathology - and PTX3 level. In the
Bruneck Study, PTX3 level emerged as unrelated to the mean
maximum IMT assessed at the common carotid, internal carotid
and femoral artery (Table 3). In line, median [interquartilerange]
PTX3 level did not differ between healthy young individuals with
or without a high IMT in the ARMY (1.63 [0.59–2.67] vs. 1.64
[0.40–2.88] ng/mL, P= 0.734) and ARFY Study (1.37 [0.68–
2.07] vs. 1.37 [0.73–2.01] ng/mL, P= 0.785). In contrast, severity
(atherosclerosis score) of carotid and femoral atherosclerosis was
found to be independently and significantly associated with PTX3
level in the Bruneck Study (Table 2). The corresponding results for
hsCRP are summarized in Table 4. In addition, PTX3 level
increased with the number of vascular beds involved in the
atherosclerosis process (P,0.001, Figure 2). The finding extends to
manifest cardiovascular disease (composite endpoint) and its
individual disease components angina, peripheral artery disease,
myocardial infarction and stroke (Figure 3). Addition of PTX3 to a
model including standard vascular risk factors improved its
Table 4. Measures of carotid and femoral artery atherosclerosis according to CRP tertile groups in the Bruneck Study.
Tertile of CRP serum level P value
Low Medium High All No CVD
Common carotid artery IMT – mm 0.9860.18 1.0060.20 1.0760.22 ,0.001 (0.052) 0.010 (0.154)
Internal carotid artery IMT – mm 0.8660.15 0.8660.17 0.9160.16 0.072 (0.410) 0.391 (0.824)
Femoral artery IMT – mm 0.9560.20 0.9860.21 1.0460.19 ,0.001 (0.006) ,0.001 (0.018)
Carotid artery AS – mm 4.0665.73 4.5465.49 6.6766.97 0.001 (0.007) 0.031 (0.118)
Femoral artery AS – mm 2.4062.61 2.1962.53 2.9662.88 0.187 (0.621) 0.167 (0.431)
Values presented are means6SD. Analyses were conducted in the entire population (All) and separately in those free of CVD (No CVD). P values are for trend and
derived from age/sex-adjusted and multivariable (adjustment see Table 3) linear regression analysis of each variable on loge-transformed PTX3 level. P values in brackets
are those from the multivariable models. AS, atherosclerosis score.
doi:10.1371/journal.pone.0031474.t004
Table 3. Measures of carotid and femoral artery atherosclerosis according to PTX3 tertile groups in the Bruneck Study.
Tertile of PTX3 serum level P value
Low Medium High All No CVD
Common carotid artery IMT – mm 1.0060.20 0.9960.19 1.0560.22 0.729 (0.940) 0.923 (0.983)
Internal carotid artery IMT – mm 0.8660.15 08760.18 0.9060.17 0.455 (0.435) 0.823 (0.844)
Femoral artery IMT – mm 0.9560.21 0.9960.20 1.0360.21 0.097 (0.174) 0.113 (0.168)
Carotid artery AS – mm 4.1165.73 4.5165.17 6.6767.23 0.002 (0.013) 0.398 (0.521)
Femoral artery AS – mm 1.9662.41 2.4562.62 3.1662.91 0.001 (0.005) 0.003 (0.009)
Values presented are means6SD. Analyses were conducted in the entire population (All) and separately in those free of CVD (No CVD). P values are for trend and
derived from age/sex-adjusted and multivariable (adjustment for age, sex, diabetes, hypertension, HDL and LDL cholesterol, smoking body mass index and waist
circumference) linear regression analysis of each variable on loge-transformed PTX3 level. P values in brackets are those from the multivariable models. AS,
atherosclerosis score.
doi:10.1371/journal.pone.0031474.t003
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predictive accuracy for cardiovascular disease (Table 5) and the
overall performance was better than that observed for hsCRP
(Table 5).
Discussion
In the large and well-defined population of the Bruneck Study,
PTX3 level showed little associations with classic and pro-
inflammatory risk parameters which contrasts to hsCRP taking
part in acute phase response and being up-regulated under a
variety of inflammatory conditions (Table 2 and [20,21]). As to
PTX3, only two correlations with neutrophil count and MMP-9
concentration remained significant after correction for multiple
testing. MMP-9 like PTX3 is primarily expressed in bone marrow-
derived cells in the atherosclerotic plaque, plays a role in the
modulation of local inflammation and contributes to plaque
destabilization.[22] High serum levels of MMP-9 have previously
been linked to femoral atherosclerosis and cardiovascular
disease.[22,23] The robust association between PTX3 level and
neutrophil count fits well to the observation that almost all
neutrophiles, infiltrating the atherosclerotic plaques and present in
coronary arterial thrombi, express PTX3.[24]
So far, PTX3 level has been proposed as a risk predictor for
acute myocardial infarction [5] and biomarker of adverse outcome
in patients with unstable angina pectoris [25], myocardial
infarction [9] and heart failure [10]. Smaller evaluations in
patients with chronic kidney disease demonstrate an association
between PTX3 levels and prevalent [26–28] as well as future [29]
CVD. In a subgroup of the Cardiovascular Health Study high
baseline PTX3 levels were linked with the subsequent risk of
cardiovascular and all cause death.[11] In line with the latter, as
well as two very recent publications [29,30], PTX3 levels were not
associated with early stage atherosclerosis (IMT) in the Bruneck,
ARMY and ARFY studies (Table 3). To the best of our knowledge
this is the first study to describe a significant and independent
association of PTX3 with advanced human atherosclerosis
(Table 3). Our findings fit particularly well to murine and human
ex vivo data suggesting pronounced PTX3 expression in advanced
but not early atherosclerotic lesions.[12,13] In the Bruneck Study,
PTX3 was independently related to both carotid and femoral
atherosclerosis and to manifest cardiovascular diseases mainly
originating from unstable plaques (Figure 3). Moreover, PTX3
level increased with the number of vascular beds involved in the
atherosclerotic process (Figure 2). Finally, preliminary data suggest
PTX3 level to be superior to hsCRP in predicting prevalent
cardiovascular disease (Table 5). However, these data have to be
viewed in light of the relatively small number of participants
(n = 562), limited number of outcome events and lack of serial
measurements of PTX3 and IMT in given individuals so far.
While the Bruneck study is representative of the general
community the ARFY study enrolled students of different
healthcare professions and thus a selected sample.
Our epidemiological study cannot establish whether the
association between high PTX levels and advanced atherosclerosis
reflects causal involvement, an epiphenomenon or counter-
regulatory protective mechanism. Experimental data support the
latter view. PTX3 knock-out mice with an atherosclerosis-prone
apoE2/2 background were shown to develop more pronounced
atherosclerosis than those expressing PTX3 with the extra
atherosclerosis being reversed by administration of PTX3.[13]
More experimental and prospective epidemiological studies are
Figure 3. Logistic regression analysis of PTX3 level on prevalent vascular diseases. Odds ratios (OR) and 95% confidence intervals (CI)
were calculated per 1 unit increase in log-transformed PTX3. Black squares denote ORs adjusted for sex and age, gray squares mark ORs adjusted for
age, sex, HDL, LDL-cholesterol, smoking, diabetes, hypertension, body mass index and waist circumference. a adjusted for age and sex. b adjusted for
age, sex, HDL, LDL-cholesterol, smoking, diabetes, hypertension, body mass index and waist circumference. c composite endpoint of stroke, TIA,
myocardial infarction, peripheral artery disease, definite angina and previous revascularization procedures.
doi:10.1371/journal.pone.0031474.g003
Figure 2. PTX3 level according to the number of vascular
territories involved in the atherosclerosis process (Bruneck
Study). Presence of atherosclerosis was determined by high-resolution
ultrasound in the (common and internal) carotid (one territory) and
femoral arteries (one territory), and on clinical grounds in the coronary
arteries (clinically overt CHD, one territory). PTX3 levels were expressed
as age and sex adjusted geometric means. Whiskers represent the 95%
confidence interval (CI). P value for trend ,0.001 (analysis adjusted for
sex and age) and P= 0.003 (analysis adjusted sex, age, HDL and LDL-
cholesterol, diabetes, smoking, hypertension, body mass index and
waist circumference). Post hoc P values for comparisons between
groups were calculated by the Dunnett T-Test.
doi:10.1371/journal.pone.0031474.g002
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needed to further establish the mechanistic role of PTX3 in
human atherosclerosis.
Conclusion
In summary, PTX3 serum level is a marker of advanced and
symptomatic but not early atherosclerosis in humans. When
compared to CRP, PTX3 predicted prevalent cardiovascular
disease better, had fewer associations with other vascular risk
conditions and may be more specific for vascular wall
inflammation.
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